MF
SRPT icon

Magnetar Financial’s Sarepta Therapeutics SRPT Stock Holding History

Magnetar Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,631
Closed -$1.89M – 1126
2025
Q1 		$1.89M Buy
29,631
+29,593
+77,876% +$3.12M 0.02% 280
2024
Q4 		$4.62K Buy
+38
New +$4.66K ﹤0.01% 587
2021
Q2 		– Sell
-6,679
Closed -$498K – 1369
2021
Q1 		$498K Buy
+6,679
New +$616K ﹤0.01% 825
2020
Q4 		– Sell
-5,037
Closed -$707K – 880
2020
Q3 		$707K Buy
+5,037
New +$765K 0.01% 387

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Magnetar Financial's SRPT Position: Q2 2025 in Review

Magnetar Financial sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 29,631 shares — an estimated $1.89M sold.

Magnetar Financial first reported a position in SRPT in Q3 2020 and held it in 4 quarters. The position peaked at $1.89M in Q1 2025. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Magnetar Financial reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Magnetar Financial sold 29,631 Sarepta Therapeutics shares in Q2 2025, an estimated $1.89M.
  • Magnetar Financial first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 4 quarters.
  • Magnetar Financial's Sarepta Therapeutics position peaked at $1.89M in Q1 2025.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Magnetar Financial's 13F filing for Q2 2025, filed 12 Aug 2025.